Indianapolis, Indiana 46202

  • Cell Lung


The purpose of this study is to determine the safety and efficacy of rhAngiostatin protein administered in combination with paclitaxel and carboplatin to patients with non-small-cell lung cancer.


Inclusion: - Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural effusions, or Stage IV NSCLC or recurrent NSCLC - No previous chemotherapy for NSCLC - Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter - Specified lab parameters - Life expectancy of at least 12 weeks - ECOG performance status of 0 or 1 - Understand requirements of study - Agree to use effective contraceptive methods Exclusion: - Have CNS metastases - Have any active cancer in addition ot NSCLC - Participated in clinical trial involving conventional or investigational drugs within previous 4 weeks - Have any contraindication to paclitaxel or carboplatin - Have had Grade 3 or greater peripheral neuropathies - Be pregnant or lactating - Have a history of myocardial infarction or angina pectoris/angina in the last 6 months - Have had significant (30 mL or more) hemoptysis with the past 3 months - Have an active infection - Have a history of bleeding diathesis, hypercoagulable condition, or an active bleeding disorder - Be receiving concurrent treatment with therapeutic doses of heparin or coumadin - Have had major surgery within 4 weeks of stating therapy - Have additional uncontrolled serious medical conditions or psychiatric illness - Received rhAngiostatin in other clinical protocols



Primary Contact:


Backup Contact:


Location Contact:

Indianapolis, Indiana 46202
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.